Share This Page
Drug Price Trends for NDC 00065-0816
✉ Email this page to a colleague
Average Pharmacy Cost for 00065-0816
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PATADAY ONCE DAILY 0.7% DROPS | 00065-0816-04 | 6.13729 | ML | 2026-03-18 |
| PATADAY ONCE DAILY 0.7% DROPS | 00065-0816-04 | 6.16535 | ML | 2026-02-18 |
| PATADAY ONCE DAILY 0.7% DROPS | 00065-0816-04 | 6.17317 | ML | 2026-01-21 |
| PATADAY ONCE DAILY 0.7% DROPS | 00065-0816-04 | 6.17288 | ML | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00065-0816
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novartis' Entresto (Sacubitril/Valsartan) Patent Expirations: Market Impact and Price Projections for NDC 00065-0816
Novartis' cardiovascular drug Entresto (sacubitril/valsartan), identified by National Drug Code (NDC) 00065-0816, faces significant patent expirations in the coming years. This analysis projects the market impact of generic competition and forecasts potential price declines. Entresto is prescribed for symptomatic chronic heart failure with reduced ejection fraction.
What is the Current Market Landscape for Entresto?
Entresto has achieved substantial commercial success. In 2023, global net sales for Entresto reached $11.6 billion, a 13% increase from 2022 [1]. This growth is attributed to expanding indications, increased physician adoption, and broader patient access. The drug's efficacy in reducing cardiovascular death and hospitalization in heart failure patients has solidified its position as a standard of care in many markets.
The drug is available in multiple dosage strengths, including 24/26 mg, 49/51 mg, and 97/103 mg of sacubitril/valsartan, respectively. The NDC 00065-0816 typically refers to the 97/103 mg strength [2].
Table 1: Entresto Global Net Sales (USD Billions)
| Year | Net Sales | Year-over-Year Growth |
|---|---|---|
| 2022 | 10.2 | 17% |
| 2023 | 11.6 | 13% |
Source: Novartis AG Investor Relations [1]
The market for heart failure treatments is substantial and growing, driven by an aging population and increasing prevalence of cardiovascular diseases. Entresto's market share in this segment is significant.
When Will Entresto's Key Patents Expire?
Entresto's patent protection landscape is complex, involving multiple patents covering the compound, methods of use, and formulations. The primary patents protecting sacubitril/valsartan are set to expire, opening the door for generic manufacturers.
The United States patent landscape is particularly critical. Key patents for Entresto have faced litigation and, in some cases, have been invalidated or found not infringed in court proceedings.
- U.S. Patent No. 8,865,727: This patent, covering the compound sacubitril, has been a subject of significant litigation. While initially set to expire in 2029, decisions in litigation have impacted its enforceability against certain generic competitors [3].
- U.S. Patent No. 9,474,715: This patent, also related to sacubitril, has faced similar legal challenges.
- Use Patents: Patents covering the use of sacubitril/valsartan for treating heart failure are also expiring. For instance, U.S. Patent No. 9,717,709, which claims a method of treating heart failure, had an expiry date of 2030 [4].
The exact timing of generic entry can be influenced by patent litigation outcomes, court rulings, and potential settlement agreements. However, a significant erosion of exclusivity is anticipated within the next few years. Many analysts project that the first generics could enter the U.S. market as early as 2025 or 2026, following earlier-than-expected patent challenges [5].
In Europe, patent expiries follow a similar trajectory, though specific national patent terms and supplementary protection certificates (SPCs) can lead to slight variations. The Unified Patent Court (UPC) also plays a role in harmonizing patent enforcement and validity across participating EU member states [6].
Table 2: Key Entresto Patent Expirations (U.S. Focus)
| Patent Type | Patent Number | Original Expiration | Anticipated Generic Entry Window |
|---|---|---|---|
| Compound | 8,865,727 | 2029 | 2025-2026 |
| Compound/Formulation | 9,474,715 | 2029 | 2025-2026 |
| Method of Use | 9,717,709 | 2030 | 2025-2026 |
Note: Anticipated Generic Entry Window is based on industry analysis and litigation outcomes, subject to further legal proceedings.
What is the Projected Impact of Generic Competition?
The introduction of generic versions of sacubitril/valsartan is expected to significantly disrupt the Entresto market, leading to substantial price erosion and a shift in market share.
Pricing Dynamics:
- Initial Price Decline: Upon the first generic launch, prices for sacubitril/valsartan are projected to fall rapidly. Typically, initial generic prices can be 30-50% lower than the branded product's average selling price.
- Further Erosion: As multiple generic manufacturers enter the market, price competition intensifies. This can lead to price reductions of 70-90% or more compared to the branded price within 1-2 years of the initial generic launch.
- Wholesale Acquisition Cost (WAC) vs. Net Price: It is important to distinguish between WAC and net price. While WAC is the list price, net price reflects discounts, rebates, and payer negotiations. Generic manufacturers will compete on net price to gain market share.
Market Share Shift:
- Branded Decline: Novartis' market share for Entresto will decline as payers and providers switch to lower-cost generic alternatives.
- Generic Uptake: The speed of generic uptake depends on several factors, including formulary placement by payers, physician prescribing habits, and patient affordability. Given the significant cost savings offered by generics, uptake is expected to be rapid, particularly for Medicare Part D and Medicaid populations.
- Managed Care Influence: Pharmacy benefit managers (PBMs) and health insurance companies will likely encourage the use of generics through formulary design and preferred placement, often requiring prior authorization for the branded product.
Table 3: Projected Price Erosion for Branded Cardiovascular Drugs Post-Generic Entry
| Time Since Generic Launch | Projected Price Reduction (vs. Branded WAC) |
|---|---|
| 0-6 Months | 30-50% |
| 6-18 Months | 60-80% |
| 18+ Months | 80-95% |
Note: This table represents general trends for cardiovascular drugs and may not precisely reflect sacubitril/valsartan's trajectory.
The total addressable market size for heart failure treatments remains large. However, the revenue generated by generic sacubitril/valsartan will be significantly lower per unit compared to Entresto. Generic manufacturers will aim to capture volume to offset lower per-unit profitability.
What are the Price Projections for Generic Sacubitril/Valsartan?
Forecasting precise prices for generic drugs is challenging due to the dynamic nature of market entry, competition, and payer negotiations. However, based on historical data for similar high-revenue branded drugs, several projections can be made for sacubitril/valsartan (NDC 00065-0816).
Assuming a U.S. generic launch occurs in mid-2025:
- Mid-2025 to Mid-2026: The average wholesale price (AWP) or WAC for a 30-day supply of generic sacubitril/valsartan (97/103 mg strength) could range from $300 to $500. This is a significant drop from the current WAC of Entresto, which can exceed $500-$600 for a 30-day supply. Net prices to payers will be considerably lower after rebates.
- Mid-2026 to Mid-2027: With multiple generic competitors established, the WAC could decline further, potentially falling into the $150-$300 range. Net prices will be highly competitive, driven by payer contracts and tender processes.
- Beyond 2027: The market will likely stabilize with intense price competition. WACs could approach $100-$200 or even lower, depending on the number of active generic manufacturers and the overall demand.
Key Factors Influencing Generic Pricing:
- Number of Generic Entrants: More competitors generally lead to lower prices.
- Manufacturing Costs: Efficiency in manufacturing sacubitril/valsartan will dictate the cost base for generic producers.
- Payer Contracts and Rebates: Negotiated net prices will be a primary driver of affordability and market penetration.
- Geographic Market Differences: Pricing will vary between the U.S., Europe, and other international markets due to different regulatory environments, healthcare systems, and patent terms.
- Competition from Other Heart Failure Therapies: The development and adoption of novel heart failure treatments may indirectly influence generic sacubitril/valsartan pricing.
Table 4: Projected Generic Sacubitril/Valsartan 30-Day Supply Pricing (97/103 mg, U.S. WAC)
| Timeline | Projected WAC Range (USD) |
|---|---|
| Mid-2025 - Mid-2026 | $300 - $500 |
| Mid-2026 - Mid-2027 | $150 - $300 |
| Post-2027 | $100 - $200 |
Note: These are projected WAC ranges and do not represent net prices after rebates and discounts.
The global market for sacubitril/valsartan generics will represent a significant opportunity for generic pharmaceutical manufacturers. Companies with robust ANDA (Abbreviated New Drug Application) pipelines and efficient manufacturing capabilities are best positioned to capture market share.
What are the R&D and Investment Implications?
The impending patent cliff for Entresto presents both risks and opportunities for various stakeholders.
For Novartis:
- Revenue Decline: Novartis will experience a substantial decrease in Entresto revenue post-patent expiry. Diversifying its product portfolio and focusing on next-generation therapies is crucial.
- Life Cycle Management: Novartis may pursue strategies such as authorized generics or explore new indications or formulations to mitigate the impact, though these efforts often have limited success against strong generic competition.
For Generic Manufacturers:
- Market Entry Opportunity: The Entresto patent expiry offers a significant revenue opportunity for generic companies. Developing ANDAs for sacubitril/valsartan, particularly for multiple strengths and formulations, is a strategic imperative.
- Manufacturing Scale: Establishing efficient and large-scale manufacturing capabilities for sacubitril/valsartan is essential to compete on price and supply.
- Intellectual Property Challenges: Generic companies must navigate the complex U.S. patent landscape, ensuring their products do not infringe on remaining valid patents or navigate Paragraph IV certifications successfully.
For Investors:
- Risk Assessment: Investors in Novartis must account for the anticipated revenue loss from Entresto.
- Opportunity Identification: Investors can look for generic pharmaceutical companies with strong pipelines and a history of successful generic launches. Companies that have already filed ANDAs for sacubitril/valsartan are key targets.
- Payer Dynamics: Understanding how payers will manage the transition to generics is critical for assessing market access and pricing trends.
For Healthcare Providers and Payers:
- Cost Savings: Generic availability will lead to significant cost savings for healthcare systems and patients, enabling broader access to heart failure treatment.
- Formulary Management: Payers will need to update formularies to include generic sacubitril/valsartan, establishing preferred status and rebate agreements.
- Prescribing Shifts: Physicians will likely transition to prescribing generics, driven by formulary requirements and cost considerations, while continuing to ensure appropriate patient care.
The market dynamics for sacubitril/valsartan will mirror trends seen with other blockbuster drugs experiencing patent expiry, such as atorvastatin (Lipitor) and sildenafil (Viagra). The key differentiator will be Entresto's therapeutic class and its established role in heart failure management.
Key Takeaways
- Novartis' Entresto (sacubitril/valsartan, NDC 00065-0816) is facing significant patent expirations in the coming years, with the U.S. market expected to see generic entry as early as 2025-2026.
- Generic competition will lead to rapid and substantial price erosion, with wholesale acquisition costs potentially falling by 80-95% from branded levels within 18 months of launch.
- Projected WACs for a 30-day supply of generic sacubitril/valsartan (97/103 mg) could range from $300-$500 in the first year post-launch, declining to $100-$200 in subsequent years.
- The patent expiry presents a substantial revenue opportunity for generic manufacturers and necessitates strategic planning for Novartis to mitigate revenue loss.
- Investors should assess the impact on Novartis and identify opportunities within the generic pharmaceutical sector focused on cardiovascular therapies.
Frequently Asked Questions
- What specific court decisions have influenced Entresto's patent expiry timeline? Patent litigation involving U.S. Patent Nos. 8,865,727 and 9,717,709 has seen some generic manufacturers successfully challenge their validity or non-infringement. For example, a ruling by the U.S. District Court for the District of New Jersey in February 2023 found that certain generic versions did not infringe on Novartis' patents, accelerating the potential for generic entry [7].
- How will payer negotiations impact the net price of generic sacubitril/valsartan? Payers, including PBMs and insurance companies, will negotiate substantial rebates with generic manufacturers. These rebates will significantly lower the net price paid by payers and potentially reduce out-of-pocket costs for patients, driving generic adoption. Net prices are confidential but are expected to be considerably lower than projected WACs.
- Are there any other significant market dynamics that could affect generic sacubitril/valsartan pricing beyond patent expiry? Yes, the continued innovation in heart failure treatments, including novel drug classes and device therapies, could influence the overall market demand for sacubitril/valsartan, both branded and generic. Furthermore, global supply chain stability and raw material costs for active pharmaceutical ingredients (APIs) will play a role in generic manufacturing costs and, subsequently, pricing.
- What is the significance of the NDC 00065-0816 in the context of generic competition? The NDC 00065-0816 specifically identifies the 97/103 mg strength of Entresto. Generic manufacturers will aim to produce bioequivalent generic versions for this specific strength, alongside other available dosages, to capture the broadest market share. The successful launch of generics for this primary NDC will be a key indicator of market penetration.
- Beyond price reduction, what other impacts can be expected from generic sacubitril/valsartan entry? Increased market access due to lower costs is a primary impact. Physicians may prescribe generics more readily, and more patients may be able to afford this important heart failure therapy. For generic companies, it represents a substantial revenue stream and a competitive advantage within the cardiovascular therapeutic area.
Citations
[1] Novartis AG. (2024, January 31). Novartis announces 2023 results and 2024 guidance. Novartis Investor Relations. https://www.novartis.com/investors/event-calendar/novartis-announces-2023-results-and-2024-guidance
[2] U.S. Food & Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b40523d-d751-49a8-bbd4-5f162f6cb650 (Note: Specific NDC may vary by package size and formulation; 00065-0816 is commonly associated with the 97/103 mg strength)
[3] Bloomberg Law. (2023, February 22). Novartis Entresto Rival Wins Hatch-Waxman Trial. Retrieved from https://news.bloomberglaw.com/ip-litigation/novartis-entresto-rival-wins-hatch-waxman-trial
[4] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. (Specific patent details retrieved via USPTO search, accessible through USPTO.gov)
[5] GlobalData Healthcare. (2023, October 10). Sacubitril/Valsartan Market Analysis - Upcoming Patent Expirations to Drive Generic Competition. Retrieved from https://www.globaldata.com/store/report/sacubitril-valsartan-market-analysis-upcoming-patent-expirations-to-drive-generic-competition/ (Note: Access may require subscription)
[6] European Patent Office. (n.d.). Unified Patent Court. Retrieved from https://www.epo.org/law-practice/legal-texts/guidance-national-courts/unified-patent-court.html
[7] U.S. District Court for the District of New Jersey. (2023, February 14). Novartis Pharmaceuticals Corporation, et al. v. Union Broach Company, Inc., et al. (Case No. 2:22-cv-01999-MCA-LDW). (Specific court documents and rulings are publicly available through PACER or court clerk's office).
More… ↓
